Contineum Therapeutics (CTNM)
Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology.
Something off on this page? Send us feedback.
Develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. Its clinical and discovery portfolio includes PIPE-791, PIPE-307 and CTX-343, with PIPE-307 subject to a global license arrangement with Janssen.
Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. The portfolio comprises clinical candidates PIPE-791, PIPE-307 and CTX-343, alongside discovery programs, within a single reportable segment.
Operations are concentrated in San Diego, while the company pursues programs for patients globally. PIPE-307 is covered by an exclusive worldwide license to Janssen; Contineum retained the right to advance it in a Phase 2 trial for relapsing-remitting multiple sclerosis.
The VISTA trial did not meet its prespecified efficacy endpoints, and Janssen has sole discretion over further PIPE-307 development for relapsing-remitting multiple sclerosis.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | Robert W. Baird | Target | Target: $14 | Target: $19 |
| May 14, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $14 | Target: $16 |
| Jan 8, 2026 | Morgan Stanley | Downgrade | Target: — | Target: $14 |
| Nov 24, 2025 | Robert W. Baird | Target | Target: $16 | Target: $14 |
| Nov 21, 2025 | RBC Capital | Reiterate | Rating: —Target: $30 | Target: $22 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $236.6M · Total debt $6.6M · Total assets $250.4M · Shareholders' equity $239.7M
- Revenue
- $0
- Operating income
- −$17.4M
- Net income
- −$15.2M
No dividends on record.
| Institutions | ≈ 81.76% | 30.76M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.44% | 166.0K shares | |
| 3 holders · as of Sep 8, 2026 | |||
| Strategic holders | 6.51% | 2.45M shares | |
| 1 holder · as of Feb 17, 2026 | |||
| Other | ≈ 11.29% | 4.25M shares | |
| remainder | |||
37.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Suvretta Capital Management, LLCInstitution | 7.55% | 2.84M A | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 7.27% | 2.73M A | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 6.51% | 2.45M | filed Feb 17, 2026 |
BlackRock, Inc.Institution | 5.49% | 2.06M A | as of Jun 30, 2026 |
Johnson & JohnsonInstitution | 5.26% | 1.98M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone | director, officer: CEO and President | −2,500 | $16.46 |
| Aug 3, 2026 | Carmine N. Stengone | director, officer: CEO and President | −2,500 | $16.01 |
| Jul 9, 2026 | Daniel S. Lorrain | officer: Chief Scientific Officer | −25 | $16.00 |
| Jul 8, 2026 | Carmine N. Stengone | director, officer: CEO and President | −2,500 | $16.00 |
| Jul 1, 2026 | Daniel S. Lorrain | officer: Chief Scientific Officer | −8,353 | $15.84 |
- Bristol-Myers Squibb
Phase 3 LPA1 antagonist developer in IPF
- MannKind
Inhaled nintedanib developer in Phase 2 IPF testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics | $13.03 | −2.76% | $504.1M | — | — | — | — |
| Bristol-Myers Squibb | $61.64 | −0.98% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| MannKind | $3.36 | −3.87% | $1.11B | — | — | 2.8 | +42.9% |
| Median | 13.7 | 9.6 | 2.7 | +24.3% |